Abstract: Exemplary embodiments relate to techniques for determining structural color from parameters of an array of nanopartides. The techniques include inputting structural and optical parameters and performing a probabilistic simulation to determine the structural color. An evolutionary optimization may be performed to determine parameters of the array of nanoparticles according to desired properties of structural color. The evolutionary optimization may employ the probabilistic simulation and further adjust one or more parameters of the array to approximate the desired properties of the structural color. Based on applying the probabilistic simulation, the technique may generate an output describing a value, or a range of values, for the one or more parameters of the array of nanoparticles that are selected to approximate the desired properties of the structural color.

Abstract: A photonic assembly for observing a preselected color includes an assembly of colloidal particles in a continuous liquid phase, the colloidal particles comprising a core scattering center and a shell layer surrounding the core, wherein the core scattering center is selected to scatter light having a predetermined wavelength, and wherein the shell has a thickness selected to provide an overall colloidal particle size that is about the same dimension as the wavelength of preselected color to be observed.

Abstract: A photonic assembly for observing a preselected color includes an assembly of colloidal particles in a continuous liquid phase, the colloidal particles comprising a core scattering center and a shell layer surrounding the core, wherein the core scattering center is selected to scatter light having a predetermined wavelength, and wherein the shell has a thickness selected to provide an overall colloidal particle size that is about the same dimension as the wavelength of preselected color to be observed.

Abstract: The present invention generally relates to foams and, in particular, to foams for applications such as drug delivery, and particles that are made from such foams. One aspect relates to foams or particles containing pharmaceutically active agents. The foam may comprise a pharmaceutically acceptable polymeric carrier. In some cases, the foam or particle has an unexpectedly high specific surface area. A high specific surface area may, in some cases, facilitate delivery or release of the pharmaceutically active agent when the foam or particles made from the foam (e.g., by milling) are administered to a subject. The foam may also exhibit a relatively high loading of the pharmaceutically active agent. In some cases, the foam may be a microcellular foam. In one set of embodiments, the foam is created using a supercritical fluid, such as supercritical C02.